These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31003171)

  • 1. Evaluation of contingency management as a strategy to improve HCV linkage to care and treatment in persons attending needle and syringe programs: A pilot study.
    Norton BL; Bachhuber MA; Singh R; Agyemang L; Arnsten JH; Cunningham CO; Litwin AH
    Int J Drug Policy; 2019 Jul; 69():1-7. PubMed ID: 31003171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs.
    E Williams B; Nelons D; Seaman A; Witkowska M; Ronan W; Wheelock H; Zaman A; Garcia J
    Int J Drug Policy; 2019 Oct; 72():138-145. PubMed ID: 30995968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.
    Arain A; Robaeys G
    World J Gastroenterol; 2014 Sep; 20(36):12722-33. PubMed ID: 25278674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
    Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
    Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
    Kåberg M; Hammarberg A; Lidman C; Weiland O
    Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
    Howell J; Traeger MW; Williams B; Layton C; Doyle JS; Latham N; Draper B; Bramwell F; Membrey D; McPherson M; Roney J; Stoové M; Thompson AJ; Hellard ME; Pedrana A
    J Viral Hepat; 2022 May; 29(5):375-384. PubMed ID: 35274403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene.
    Gunn J; McNally S; Ryan J; Layton C; Bryant M; Walker S; O'Mahony C; Pedrana A
    Int J Drug Policy; 2021 Oct; 96():103387. PubMed ID: 34330571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.
    Schulkind J; Stephens B; Ahmad F; Johnston L; Hutchinson S; Thain D; Ward Z; Vickerman P; Hickman M; Dillon JF
    J Viral Hepat; 2019 May; 26(5):519-528. PubMed ID: 30422370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.
    Semá Baltazar C; Boothe M; Kellogg T; Ricardo P; Sathane I; Fazito E; Raymond HF; Temmerman M; Luchters S
    BMC Public Health; 2020 Jun; 20(1):851. PubMed ID: 32493347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.
    Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L
    J Viral Hepat; 2014 Mar; 21(3):198-207. PubMed ID: 24438681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
    Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH
    Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection.
    Beer L; Inglis S; Malaguti A; Byrne C; Sharkey C; Robinson E; Gillings K; Radley A; Hapca A; Stephens B; Dillon J
    J Viral Hepat; 2022 Aug; 29(8):646-653. PubMed ID: 35582875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
    Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J;
    Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden.
    Kågström E; Lannergård A; El Khosht J; Lörelius P; Månflod J; Strömdahl S
    Harm Reduct J; 2023 Jun; 20(1):77. PubMed ID: 37328868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).
    Fadnes LT; Aas CF; Vold JH; Ohldieck C; Leiva RA; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
    BMC Infect Dis; 2019 Nov; 19(1):943. PubMed ID: 31703669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation.
    Schwarz T; Horváth I; Fenz L; Schmutterer I; Rosian-Schikuta I; Mårdh O
    Int J Drug Policy; 2022 Apr; 102():103588. PubMed ID: 35101667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injection risk norms and practices among migrant Puerto Rican people who inject drugs in New York City: The limits of acculturation theory.
    Gelpí-Acosta C; Guarino H; Benoit E; Deren S; Pouget ER; Rodríguez A
    Int J Drug Policy; 2019 Jul; 69():60-69. PubMed ID: 31196730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.